RayzeBio, Inc. (NasdaqGM: RYZB)
Health Care · Biotechnology · US
$—
— today · — 1Y
RayzeBio, Inc. (NasdaqGM: RYZB) operates in the Biotechnology industry within the Health Care sector.
RYZB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -8.77
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 88
- Next earnings
- —
About RayzeBio, Inc.
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
- ISIN
- US75525N1072
- Founded
- 2020
- Listed since
- Sep 15, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.61 | -1.57% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.27 | +0.01% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.80 | +0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.52 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.79 | -1.17% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.35 | -7.86% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.